Marco Solmi’s Post

Superstar singer Celine Dion announced that she has #StiffPersonSyndrome—a rare neurological disorde, an #autoimmune condition. I am testing for antibodies and I am finding an increase of autoimmunity in my clients. Physicians, alternative providers should check for autoimmunity, especially on those patients that had #Covid illness or #Covidvaccine. In the five-minute post, Dion shared how Stiff-Person Syndrome was causing spasms that affect her ability to walk and sing. “I’ve been dealing with problems with my health for a long time" says Dion. Dr. Kottil Rammohan, a professor of clinical neurology and the past director of the Multiple Sclerosis Center of Excellence at the University of Miami Miller School of Medicine, explained Stiff-Person Syndrome and its treatment. What is Stiff-Person Syndrome? Stiff-Person Syndrome is an extremely rare neurological disorder. And no one really knows the exact prevalence, but it is thought to be like one to two per million. How is Stiff-Person Syndrome diagnosed?. There have been new tests that have identified specific #antibodies in people. The presence of these antibodies can present without Stiff-Person Syndrome and the antibodies can be a marker—so it goes both ways. The antibodies are called anti-glutamic acid decarboxylase (GAD) and anti-amphiphysin antibodies. GAD is an important enzyme that assists in the production of a glutamic acid to gamma amino butyric acid (GABA), the main inhibitory neurotransmitter of the brain. Is there a treatment for it? What are some ways to manage the symptoms? You can manage the symptoms and also treat the underlying problem of the offending antibody. First, of course, is giving something to relax the muscles. Something like Valium, which is excellent for this condition, or Baclofen. After treating for the muscle spasms, it is important to try to remove the offending antibody. The treatment involves plasma exchange or giving medications to modulate the immune system, including drugs like intravenous #immunoglobulin or anti B cell therapies. Diet #Glutenfree and #dairyfree (especially to avoy cow's milk and cheese, instead use dairy from goats and sheep). #Bonebroth contains #glutamine to heal the leaky gut, #vitaminC flush to remove toxins and bad bacteria, avoid #stress, # practice daily #breathing technique to go into from fight and flight into rest and digest, fix nutrient deficiencies, have at least 6 hours of good #sleep. Because Stiff-Person Syndrome is so rare, how important is it for someone like Celine Dion to raise awareness about this disease? Without a doubt, it is important for not only her, but even physicians, to bring awareness to the disease. https://lnkd.in/dxM927eR

Hypertensive intracerebral hemorrhages in the Republic of Tatarstan in 2022: neurological deficit and the share of aggressive intracerebral hemorrhages The article presents the results of a study on neurological disorders in patients with hypertensive intracerebral hematomas in the Republic of Tatarstan and the proportion of aggressive intracerebral hematomas requiring surgical treatment. A retrospective multicenter study was conducted, including data of 1,127 patients with hypertensive intracerebral hemorrhages from 4 regional vascular centers and 14 primary vascular centers in the Republic of Tatarstan in 2022. Motor disorders were observed in 86.3 % of patients, speech disorders — in 73 %, general cerebral symptoms — in 86.1 %, eye movement disorders — in 17.1 %, vestibular disorders — in 7.5 %, bulbar disorders — in 7.3 %, visual disturbances — in 7 %, generalized seizures at the onset of the disease — in 5.5 %, and mental disorders — in 2.9 % of the patients. At the time of admission to the vascular center, 13.1 % of the patients with an aggressive intracerebral hemorrhage were considered potential candidates for surgical treatment, and within the next day after hospitalization, this figure was 10.9 %. The hospital mortality of patients with hypertensive intracerebral hemorrhages with a Glasgow Coma Scale score of 8 or less upon admission was 4.7 times higher than that of patients with a Glasgow Coma Scale score of more than 8 points. https://lnkd.in/eHSqWdAF

Safety and efficacy of inebilizumab for the treatment of neuromyelitis optica spectrum disorder: end-of-study results from the open-label period of the N-MOmentum trial Safety and Efficacy of Inebilizumab for Neuromyelitis Optica Spectrum Disorder End-of-Study Results from N-MOmentum Trial In a recent study published in Lancet Neurology, the safety and efficacy of inebilizumab for treating neuromyelitis optica spectrum disorder were investigated. The study included both the randomised controlled period and the open-label extension period. Key Findings 225 participants received inebilizumab, with 208 being AQP4-IgG seropositive. Over a 4-year period, 63 adjudicated neuromyelitis optica spectrum disorder attacks occurred in 47 participants, with 40 attacks occurring in the first year. Annualised attack rates decreased year-on-year, and most participants who had an attack while receiving inebilizumab were subsequently attack-free at the end of 4 years. Overall, 92% of participants who received inebilizumab experienced at least one treatment-emergent adverse event, with urinary tract infection, nasopharyngitis, and arthralgia being the most frequent. Implications The end-of-study analysis showed sustained clinical benefits of long-term inebilizumab treatment for individuals with neuromyelitis optica spectrum disorder. This supports the role of inebilizumab as a CD19+ B-cell-depleting therapy in this disorder. For more information about how our AI-driven platform, DocSym, can help consolidate clinical knowledge and streamline healthcare operations, visit aidevmd.com. https://lnkd.in/gQEtRxvb #ClinicalTrials #AIinHealthcare #MedicalAI #HealthTech #DigitalHealth #PatientCareAI #AIResearch #MedicalInnovation #BioTech #AIforGood #HealthcareData #AIinMedicine #PharmaAI #ClinicalData #HealthAI #AIHealthSolutions #PrecisionMedicine #AIandHealth #ClinicalAnalytics #AIDiagnostics

📢 New Research Publication Alert 📢 A recent study from researchers at University Hospitals (UH) Connor Whole Health and Rainbow Babies & Children’s Hospital describes a quality improvement project where pain screening procedures were embedded within an outpatient pediatric sickle cell disease (SCD) clinic. Investigators found that the pain screening procedures were feasible when implemented within routine outpatient care. Of the 104 patients screened, 32.7% reported persistent or chronic pain, and 46.2% reported medium or high risk for persistent symptoms and disability. When asked about their preferences for integrative modalities, patients expressed highest interest in music therapy (55.6%) and art therapy (51.9%) and preferred in-person (81.5%) over virtual programming (22.2%). “What this study adds is a systematic process for us to identify patients at high risk for persistent pain symptoms and disability early so that we can intervene and equip adolescents and young adults with SCD with the skills needed to better manage their pain,” said Samuel Rodgers-Melnick, MPH, MT-BC, co-author of the study. Click the link to read the article "Pain screening in youth with sickle cell disease: A quality improvement study" in Pediatric Blood and Cancer: https://lnkd.in/eZ3GbTWy #sicklecelldisease #painmanagement #research

📉A new study from China's Southern Medical University using data from the Look AHEAD trial found that moderate to vigorous exercise improved renal function in patients with diabetes and mild renal dysfunction. Care managers can provide important encouragement to patients to help them stick with an exercise program and avoid progression to CKD. 🏃♀️ What strategies are most effective in your practice? #ckd #chronickidneydisease #nephrology #primarycare #caremanagement Boosting physical activity lowers CKD risk in patients with diabetes https://hubs.li/Q02lD7zn0

Global, regional, and national burden of disorders affecting the nervous system, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021 "The ten conditions with the highest age-standardised DALYs in 2021 were stroke, neonatal encephalopathy, migraine, Alzheimer's disease and other dementias, diabetic neuropathy, meningitis, epilepsy, neurological complications due to preterm birth, autism spectrum disorder, and nervous system cancer." GBD 2021 Nervous System Disorders Collaborators (2024). Global, regional, and national burden of disorders affecting the nervous system, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021. The Lancet. Neurology, S1474-4422(24)00038-3. Advance online publication. https://lnkd.in/dBk-TJej

🧠We welcome the great systematic literature review by Professor Helen Cross and team, into the huge burden that Lennox Gastaut Epilepsy Stndrome and Developmental and Epileptic encephalopathy has on people with epilepsy, their caregivers and the wider societal issues. 🚶♀️More research is desperately needed to address the unmet need for causative factors of seizures and associated conditions such as intellectual disability, autism, sleep, mobility, gastrointestinal issues, immune and hormone health. 🥗Integrative therapies including Nutritional Therapy, mental health, psychotherapy, immunology, urology, gastroenterology should be utilised more to support the quality of life on multiple levels. #lgs #epilepsyawareness #epilepsy #epilepsywarrior #nutritionaltherapy #bant https://lnkd.in/eCsvDJ4x

Yale researchers studied Long COVID patients with internal tremor symptoms, the effect of having other medical conditions prior to COVID-19, and the onset of new conditions. Of 423 Long COVID study participants, 37% described having internal tremors or vibrations. Gender was the only statistically significant demographic factor that was identified—of the study group, 81% of female participants reported internal tremors as a symptom compared to 70% of male participants. Importantly, participants with internal tremors reported significantly worse Long COVID symptom severity and had higher rates of experiencing such additional wide-ranging symptoms as visual flashes of light, hair loss, tingling or numbness, chest pain, and ringing in the ears. Participants with internal tremors reported higher rates of new-onset mast cell disorders, a group of diseases in which mast cells are abnormally active and typically cause symptoms such as itching, nausea, and abdominal pain. Participants also reported higher rates of new-onset neurological disorders and conditions, including seizures and dementia, as well as stress and anxiety disorders compared to Long COVID participants without internal tremors. A possible treatment Currently, low-dose naltrexone (LDN), a drug that has been used to treat chronic pain and discomfort in fibromyalgia and other rheumatological disorders, is sometimes used to relieve internal tremors and vibrations in Long COVID patients with varying levels of success. When administered in a daily dose of 1 to 5 mg, naltrexone is thought to reduce inflammation, release endorphins, and normalize cortisol levels to alleviate discomfort. At its usual dose—50 mg or greater—naltrexone is used to treat addiction. In one study, 52 participants with Long COVID were treated with a two-month course of LDN. The researchers conducted a survey and found that the participants reported an improvement in Long COVID recovery, daily activity limitation, energy levels, pain levels, concentration levels, and sleep disturbance. The study concluded that LDN was safe to use in Long COVID patients but required additional randomized control trials to validate its therapeutic use. https://lnkd.in/eWjwW9RB NEED SUPPORT? ProMedView coaches and advocates can help you: • Document your symptoms • Review your medical records • Find legal, medical, & mental health resources • Navigate your recovery Learn more at https://lnkd.in/dXBhFW8v #longcovidvibrations #internalvibrations #longcovidtremors

SSRIs and SNRIs have been shown to reduce neural inflammation and restore hormone balance. After Covid-19 infection, 12.5% develops post-Covid-syndrome (PCS). Symptoms indicate numerous affected organ systems. After a year, chronic fatigue, dysautonomia and neurological and neuropsychiatric complaints predominate. In this study, 95 PCS patients were treated with selective serotonin reuptake inhibitors (SSRIs). This study used an exploratory questionnaire and found that two-thirds of patients had a reasonably good to strong response on SSRIs, over a quarter of patients had moderate response, while 10% reported no response. Overall, patients experienced substantial improved well-being. Brainfog and sensory overload decreased most, followed by chronic fatigue and dysautonomia. Outcomes were measured with three different measures that correlated strongly with each other. The response to SSRIs in PCS conditions was explained by seven possible neurobiological mechanisms based on recent literature on PCS integrated with already existing knowledge. Important for understanding these mechanisms is the underlying biochemical interaction between various neurotransmitter systems and parts of the immune system, and their dysregulation in PCS. The main link appears to be with the metabolic kynurenine pathway (KP) which interacts extensively with the immune system. The KP uses the same precursor as serotonin: tryptophan. The KP is overactive in PCS which maintains inflammation and which causes a lack of tryptophan. Finally, potential avenues for future research to advance this line of clinical research are discussed. [Treatment of 95 post-Covid patients with SSRIs - Nature](https://lnkd.in/eVMDJXJd)

Understanding and Addressing Cognitive Dysfunction in Long Covid Patients By Dr. Jessica Nelson Overview of Cognitive Dysfunction in Long Covid Patients Cognitive problems are a common occurrence after acute SARS-CoV-2 infection and can have disabling and frightening effects on individuals. These symptoms can severely impact the daily functioning and quality of life of those affected. Doctors are facing the challenge of approaching cognitive dysfunction in patients with #LongCovid, as the long-term effects of the virus on cognitive function are still being understood. It is important for healthcare professionals to closely monitor and assess cognitive symptoms in patients with Long Covid, and to provide appropriate support and interventions to address these issues. Unveiling the Unseen Fallout: Studies and Findings A study aimed to quantify cognitive deficits in patients with post-acute sequelae of Covid-19 (PASC) and identify key variables related to cognitive impairment in PASC. The study found that patients with PASC were almost 4 times more likely to evidence cognitive dysfunction compared to normal controls, with 44% of patients demonstrating cognitive deficits about 7 months from infection. Higher Body Mass Index (BMI) was the only metric shown to differentiate those with PASC and cognitive impairment from those with PASC who were cognitively intact. A recent study published in the journal EClinicalMedicine by a team of scientists from Germany assessed the long-term trajectories of sequelae of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections such as cognitive deficits and fatigue. The study included 3,000 patients and found that while both symptoms showed improvements over a span of two years in approximately 50% of the patients, specific risk factors such as depressive symptoms and headache predicted non-recovery from fatigue in the long term. Old age and male sex were two of the risk factors indicating non-recovery from cognitive deficits in long COVID patients. A study on the relationship between systemic inflammation and neuroaxonal damage in patients with severe COVID-19 and its impact on long-term cognitive impairment was conducted. The study found that prolonged systemic inflammation in critically ill COVID-19 patients is related to neuroaxonal damage and subsequent long-term cognitive impairment. Plasma NfL concentrations during ICU stay may possess prognostic value in predicting future long-term cognitive impairment in patients that survived severe COVID-19. Long COVID as a Viral-Borne Brain Injury ***Click on image below to access the rest of this study. Posted on MLCA by Larry Cole